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Глаукома: что необходимо знать каждому пациенту.  
Часть 2. Факторы, повышающие вероятность развития 
закрытоугольной глаукомы. Ослепнете ли вы? Лечится ли 
глаукома? Как помочь своим близким уменьшить вред, 
наносимый глаукомой? 
Abstract 
The first part of the article describes various factors 
increasing the risk for angle closure glaucoma, such as 
older age, female sex, being Asian, having blood relatives 
with glaucoma, having smaller eyes (far-sightedness) and 
individual features of the eye. It emphasizes that angle clo-
sure glaucoma is more a disease of higher than normal eye 
pressure than is open angle glaucoma. The author explicates 
in comprehensible anatomic details the process, mechanism 
and first means of treatment of angle closure, specifics 
of hyperopic eyes, the nature of pupil block. 
In the next part of the article the author answers the 
most pressing question for all glaucoma patients: will I be 
blind? He explains that though glaucoma presents a real 
threat to the vision of anyone who develops it, if a person 
continues to follow the standard care instructions, there is 
a good chance that he will preserve much of his sight until 
the end of his life. At the same time the author emphasizes 
the irreversibility of the vision loss and the importance of 
adhering with the treatment program, describes several 
characteristic signs and symptoms of glaucoma, and gives 
a brief account of the anatomical reasons behind them. 
Vision loss statistics is also presented.
The next section forms of definitive treatment for glau-
coma are discussed. Today restoring the lost vision still 
remains a future hope, however, present treatments can 
slow the process so much that no meaningful loss might 
occur in the person’s lifetime. Successful glaucoma surgery 
can lower eye pressure to a safe level, but it is important to 
keep having doctor’s exams regularly even when successful 
surgery has been done. The other kind of successful treat-
ment for most persons with glaucoma is to take daily eye 
drops indefinitely. Several hypothetic ways of prolonging 
the effect of glaucoma medicine are discussed, such as 
long-lasting drugs and virus particles carriers. Current neu-
roprotection therapy research and the initial steps of nerve 
cell replacement are also mentioned. 
The last part of the article gives an account of genetic 
background of glaucoma and present research of genetic 
risk factors, and underlines the importance of intrafamilial 
information sharing and regular glaucoma check-ups.
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Factors increasing the risk for angle closure 
glaucoma
 •  Older age (again)
 •  Female sex (that’s different)
 •  Being Asian
 •  Having blood relatives with it
 •  Having smaller eyes (far-sightedness)
 •   Features of how internal eye structures behave 
(iris, choroid)
As with open angle glaucoma, older persons are 
more likely to have angle closure. We have seen people 
in their twenties with the disease, but that is very rare. 
The rate peaks around age 60 or so, at least in part 
because the natural tendency is for eyes to get short-
er (slightly smaller) with time. By contrast with open 
angle glaucoma, angle closure affects women probably 
50% more often than men. The reasons for this aren’t 
completely settled, but we do know that women have 
smaller eyes and that is one of the contributors.
For reasons that aren’t yet fully understood, Asian 
persons have a lot more angle closure than everyone 
else in the world, though it may be that east Indians 
also have a greater risk. Asians don’t have more of the 
other risk factors; at least present research says that 
their eyes don’t have more of the other contributing 
factors, such as more persons with smaller eyes. Asian 
eyes look a little different from Europeans because they 
have different eyelid structure, not because their eyes 
themselves are a different size. The contribution of 
family history (genetics) to angle closure is real, but not 
as well studied as for open angle glaucoma. No actual 
mutations or DNA code mistakes in particular genes are 
known that are associated with angle closure yet. With-
out question, however, if your mom (or another close 
blood relative) had it, you are at least somewhat more 
likely to have angle closure as well.
Angle closure glaucoma is more a disease of higher 
than normal eye pressure than is open angle glaucoma. 
As discussed in a previous section, the process of angle 
closure means that the iris moves to block the trabe-
cular meshwork, raising eye pressure and causing da-
mage. This can happen either suddenly (an acute angle 
closure crisis) or more commonly as a silent but off-
and-on process that gradually plugs up the meshwork 
with iris stuck to it, leading to a chronic disorder. The 
dominant reason for the iris to block the meshwork is 
that it starts out close to the outflow area in the first 
place in smaller eyes. Smaller eyes are often “far-sight-
ed” (hyperopic). Persons with hyperopia develop the 
need for eyeglasses in mid-life and become unable to 
read print without glasses earlier than everyone else. 
When we measure the length of their eyes, they are 
shorter than average, with crowding of the structures 
together. This slows the movement of aqueous humor 
from where it is produced behind the iris (at the cili-
ary body) through the pupil (between the iris and lens) 
and into the front chamber (anterior chamber) of the 
eye. Because the block of aqueous movement is at the 
pupil, doctors call it pupil block. If there were an open-
ing in the iris, the fluid couldn’t be blocked — so the 
Резюме 
В первой части статьи описываются различные факто-
ры, повышающие вероятность развития закрытоугольной 
глаукомы, такие как возраст, женский пол, принадлежность 
к монголоидной расе, маленький размер глаза (гиперме-
тропия), а также индивидуальные черты. Подчеркивается, 
что закрытоугольная глаукома в большей степени, чем 
открытоугольная, является болезнью повышенного вну-
триглазного давления. Автор объясняет в доступных анато-
мических подробностях детали, механизм развития и пер-
вичное лечение при закрытоугольной глаукоме, специфику 
гиперметропичных глаз и природу зрачкового блока.
В следующей части статьи автор отвечает на главный 
для большинства пациентов с глаукомой вопрос: «Могу 
ли я потерять зрение?» Он объясняет, что, несмотря на 
то что глаукома представляет собой большую опасность 
для зрения, при соблюдении необходимых схем лечения 
всегда остается шанс на сохранение большого процента 
зрения до конца жизни. В то же время подчеркивается 
необратимость потери зрения при глаукоме и необходи-
мость неукоснительного соблюдения назначенного лече-
ния. Описываются несколько характерных для глаукомы 
признаков и симптомов, дается их анатомическое объ-
яснение. Приводится краткая статистика потери зрения 
вследствие глаукомы.
В третьей части статьи обсуждаются существующие 
формы лечения глаукомы. На сегодняшний день вос-
становление уже утраченного зрения остается недости-
жимым, однако современное лечение может настолько 
замедлить прогрессирование глаукоматозного процес-
са, что представляется возможным сохранение боль-
шего процента зрения в течение всей жизни человека. 
Успешное хирургическое лечение глаукомы может сни-
жать внутриглазное давление до безопасного уровня, 
однако не отменяет необходимости регулярного динами-
ческого наблюдения и после операции. Одним из основ-
ных способов успешного лечения данного заболевания 
является пожизненное закапывание глазных капель. 
Также в статье описываются находящиеся в разработке 
способы продления эффекта терапии глаукомы, такие 
как лекарственные средства увеличенной продолжитель-
ности и применяющиеся в генной инженерии вирусные 
частицы-носители. Также упоминаются современные 
исследования в области нейропротекторной терапии гла-
укомы и первые шаги в возможной замене нервных кле-
ток при этом заболевании.
Заключающая часть статьи рассказывает о возмож-
ной генетической предрасположенности к глаукоме и 
текущих поисках генетических факторов риска, а также 
подчеркивает важность информирования родственников 
о диагностированной глаукоме и регулярных обследова-
ний для выявления заболевания.
КЛЮЧЕВЫЕ СЛОВА: глаукома, закрытоугольная глау-
кома, факторы риска, внутриглазное давление, динами-
ческое наблюдение.
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first treatment for angle closure is to make a hole where 
there isn’t one naturally. This is done in the office with 
a laser, pretty painlessly, with only eyedrop anesthesia.
More detail about the risk of developing angle 
closure glaucoma and treatment or no treatment for 
suspects for angle closure is included in the section 
“Why isn’t glaucoma either there or not there — what 
makes you an angle closure suspect”?
Will you go blind?
Take Home Points
 •  Odds of going blind are low
 •  Once damage happens it can’t be fixed
 •   Relatively more blindness from angle closure 
than open angle glaucoma
 •  We must prevent damage before it happens
 •   Adherence with the treatment program 
improves your chances
If you are like many persons that we have cared 
for, one of the first thoughts you have when present-
ed with the knowledge that you have glaucoma is: will 
I be blind? The good news is that if you are not blind 
at this time, there is a very good chance that you will 
never be blind, at least from glaucoma. It is true that 
glaucoma is the second leading cause of blindness in 
the world after cataract. And, it presents a real threat 
to the vision of anyone who develops it. But from scien-
tific studies all over the world and among persons just 
like you, we can say that the vast majority of persons 
who know that they have glaucoma, and who continue 
to follow the standard care instructions, will arrive 
at the end of their lives still reading and seeing well 
enough to enjoy life from both eyes.
Once we are adults, we don’t grow any new cells in 
our brain. Since glaucoma kills nerve cells that are truly 
part of the brain, it is not surprising that once vision is lost 
from glaucoma, it cannot be restored. The nerve cells that 
are dead were part of an intricate network in the retina 
and had a long fiber stretching inches up into the brain 
to begin a visual process that is more complex than we 
can even imagine now. Our best hope for the glaucoma 
patient, and the goal of treatment, is to save the vision 
that is left. We can do that to such an extent that most of 
those with glaucoma will live normal visual lives. Research 
in our laboratories and in others is presently working very 
hard to find ways to restore lost vision from glaucoma 
and other diseases, but at present nothing can be done to 
return vision that has been lost from glaucoma.
Actual statistics show that about 5% of European-
derived persons with glaucoma will lose the ability to 
read standard print in both eyes from open angle glau-
coma. The number is 3 times higher among African-
Americans. And, it is also 2-3 times higher for those 
with angle closure glaucoma. But, many of this small 
percentage who become blind are those who were near-
ly blind before they found out that they had glaucoma. 
A famous glaucoma specialist from Boston, Morton 
Grant, wrote about his many years of seeing and study-
ing glaucoma. He concluded that those few patients 
who did badly and lost their vision from glaucoma 
were most often those who didn’t follow care instruc-
tions or who came to the doctor too late. For the per-
sons in that group, we have included a section “What 
does low vision treatment have to offer?”
Again, looking at real statistics, about 15% of glau-
coma patients will lose the ability to read in one eye. 
That is a tragedy for them and hurts their ability to do 
some things that require vision to see in 3 dimensions, 
what is called depth perception. Having lost one eye, 
one is more likely to knock over the salt shaker at din-
ner, or to stumble on stairs and curbs. Glaucoma dam-
age decreases the contrast sensitivity of the vision sys-
tem, so what seemed like a black and white page of 
print before is now more grey and white. Glare is more 
of a problem for the glaucoma patient. And, you must 
develop methods to adjust to changes in lighting when 
moving from bright sunshine to dark interiors, or the 
other way around. Each of these effects is due to the 
loss of some ganglion cells from the retina in the eye.
Glaucoma is most likely to affect one eye much 
more than the other. We don’t know why this is, since 
both eyes have seemingly been exposed to the same 
environment, diet and use. My mom went to the ortho-
pedic surgeon with pain in her right knee. She asked 
the doctor: “why is my knee hurting?” and he answered: 
“Well, Mrs. Quigley you’re 80 years old.” She said: 
“The other knee’s 80, too, and it doesn’t hurt!” But, it 
turns out to be fortunate that glaucoma affects one eye 
more, since damage mostly in one eye with the other 
eye unaffected leaves the person pretty functionally 
normal. Our research at the Glaucoma Center of Excel-
lence has been instrumental in showing how glaucoma 
affects persons’ lives in the real world. Those with one 
eye that is largely intact can do most daily activities as 
well as persons with two good eyes. While they must 
maintain a higher level of alertness, driving and walk-
ing are largely done just as well and safely by early and 
moderate glaucoma patients as their equal aged broth-
ers and sisters with two good eyes.
The areas of vision affected by glaucoma are fortu-
nately not in the center part of our world where we read 
and watch televisions and computers. The zones where 
the early dying nerve cells see the environment are in 
the middle areas, not the center and not at the extreme 
outside of our peripheral vision. Since the brain nor-
mally gets input from both eyes about every place in 
our immediate world, as long as one eye is providing 
the picture of a zone, the brain isn’t missing anything. 
This explains something that puzzles patients when 
they see their visual field testing from each eye. The 
doctor shows them black areas (areas where the eye 
cannot see) in one eye, yet as far as the patient is con-
cerned there are no such black areas or missing spots 
in their real world when they are looking with both 
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eyes. That’s good for continuing to function normally, 
but it is one reason why people don’t notice their own 
glaucoma damage until very late in the injury process. 
If the left eye still sees what the right eye is missing, 
damage in the right eye is not noticed. And, the damage 
happens so slowly that the person has time to adjust 
to the change without realizing it is happening. When 
we measured those with severe glaucoma damage in 
both eyes on a walking course, the person bumped into 
things more and walked more slowly than those of the 
same age. When we asked them if they had any trouble 
walking, they said: “No” — because they had realized 
gradually that walking had become more difficult, but 
had taken it for granted that it was due to old age.
There is very active research to determine what 
effects glaucoma has on important activities of daily 
living. We often hear from patients that they are hav-
ing more difficulty with reading, for example. When 
we measure their acuity on the letter chart on the wall, 
they have normal 20/20 vision. Perhaps the subtle loss 
of nerve cells near the central vision, or other effects of 
glaucoma, do actually impair reading. We have deter-
mined that glaucoma patients can start reading at a nor-
mal pace, but slow significantly within 15-20 minutes. 
Glaucoma patients also give up driving earlier than per-
sons of the same age without vision problems. Driving 
a car is a vital personal activity that determines in many 
ways the ability to live independently in our society. We 
need to determine which patients should, in fact, stop 
driving, and which ones can continue to do so safely.
While it is true that most glaucoma patients don’t 
get to a stage of severe vision loss, there is a slow wor-
sening of vision function in some glaucoma patients 
with time, even when appropriate treatment is given. 
This worsening is so minor in the majority that we can 
feel confident they will not be impaired in their life-
time. But, a minority of those with glaucoma progres-
sively worsens at a rate much greater than the rest. For 
the slow progressors, standard treatment is perfectly 
sufficient, while for the rarer ones with more aggres-
sive disease, treatment must also be aggressive. As we 
deal with the examining techniques and treatments for 
glaucoma in the next sections, it will become clearer 
that “one size doesn’t fit all” for glaucoma treatment. 
Some need only regular examinations and don’t even 
need pressure lowering therapy, while others must 
undergo surgery to save vision. But, whichever group 
one falls into, vision should be able to be saved with 
a good program jointly agreed to by doctor and patient.
Can glaucoma be cured?
Take Home Points
 •  There is presently no cure
 •   Successful treatment can stop meaningful 
vision loss
 •   Nerve cell replacement research has taken  
initial steps
When she was 90 years old, my wonderful Grand-
ma Mamie told me she was having trouble putting on 
pullover sweaters because her shoulders had arthritis. 
“Harry,” she asked, “you’re at that medical school Johns 
Hopkins, when is my shoulder going to get better?” 
I had to help her understand that we weren’t going 
to cure her shoulder, but we could buy her button-up 
sweaters. An important part of helping persons with 
glaucoma is to channel that hopefulness that Mamie 
expressed into flexibility to deal with what they’ve got. 
(Mamie kept winning at Bingo and playing bridge for 
some time afterward).
In this section, we’ll discuss two forms of definitive 
treatment for glaucoma, one may happen in the future, 
and one is what we can do now. The future hope is to 
restore vision that has been lost. That can’t present-
ly be done. The present treatments can slow the pro-
cess so much that no meaningful loss occurs in the per-
son’s lifetime. Successful glaucoma surgery can lower 
eye pressure to a safe level (Operations for glaucoma). 
Such surgery can last for many years without need for 
any eye drops or medicines. But, since there are some 
surgery eyes that start needing medicine or more sur-
gery again later, it is important to keep having doctor’s 
exams regularly even when successful surgery has been 
done. So, checkups will be needed, just as they are for 
other serious illnesses where a remission has been pro-
duced, to be sure it doesn’t come back. For now, we 
have several ways to lower eye pressure to really slow 
vision loss from glaucoma.
As described already, the successful treatment for 
most persons with glaucoma is to take daily eye drops 
indefinitely. Several laboratories and companies are 
presently working on a variety of ways that the me-
dicine for glaucoma could be given only once or twice 
per year. These approaches will probably include plac-
ing the medicine as a deposit under the surface of the 
eye or even inside the eye in the doctor’s office under 
sterile conditions. This may sound scary, but for anoth-
er eye disease called age-related macular degenera-
tion, inside the eye injections every month are already 
proving to be a sight restoring method that older per-
sons find easy to tolerate. This could really increase the 
number of those with glaucoma who no longer need 
to take eye drops every day.
There are several things that could be placed on 
or in the eye that could help. Some would be drugs in 
a long-lasting formula that lower eye pressure. Others 
would be carriers made from modified virus particles 
that get inside the eye cells in the front or back of the 
eye. Once inside these viral carriers fool the cells into 
thinking that the DNA they carry should be translated 
like a normal gene and the substance that is produced 
is made by the cell as if it were a natural molecule. The 
Glaucoma Center of Excellence team has already test-
ed several such molecules that slow glaucoma damage 
in animal models of glaucoma. Ideally, one injection of 
such a viral carrier would last for years to protect the 
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eye. This may sound like Star Wars, but one eye disease 
called Leber’s congenital amaurosis has already been 
helped dramatically in human eyes by this type of 
approach. People with that disease have the fortunate 
situation that when the viral carrier was injected, they 
actually saw better. This insertion of DNA is called gene 
therapy, and there are active research programs to use 
this approach for glaucoma.
Gene therapy is only one of the things now being 
included in the approach called neuroprotection 
research for glaucoma. This type of treatment, when 
it becomes available, will involve any method that 
keeps nerve cells alive longer — and preserves the 
vision that the person has at that time. But, gene the-
rapy and neuroprotection will not restore lost vision. 
In general, these methods do not try to lower eye pres-
sure, but rather they make the eye or the nerve cells 
less likely to suffer from the effects of eye pressure 
and the other negative things that glaucoma does. We 
now have more than a dozen types of potential neuro-
protective drugs that have been shown to work in this 
way in mice, rats, and even monkeys. One full trial of 
a drug called Memantine in over 1,000 patients was 
conducted to see if the pill would slow the rate of 
peripheral visual loss in glaucoma patients. The drug 
didn’t work well enough to be recommended for 
patients with glaucoma, but some large drug compa-
nies are actively researching this area. A very small 
study tested whether one of our existing eye drops for 
glaucoma has additional benefit as a neuroprotectant. 
Unfortunately, the data require confirmation before we 
can be sure what was found. When we talk to glaucoma 
patients and their families, there is often a wonderful 
hopefulness that adding some treatment to the standard 
approaches will be helpful. Consideration of the things 
that are called “alternative therapies” is given in section 
Are there treatments other than lowering eye pressure?
Standard glaucoma treatment has been shown 
to slow the progress of the disease in the majority of 
patients to such an extent that they never become more 
impaired than they are at the time they discover they 
have the disease. That isn’t a cure, but it is a comfort. 
But, for those who have very significant vision loss 
from glaucoma, the hope is that we will find a way to 
restore vision. For some eye problems, there are actual 
improvements to be expected from treatment. Cataract 
means that the lens inside the eye has become cloud-
ed. Surgery is commonly done to remove the foggy lens 
and replace it with an artificial one. Cataract surgery 
routinely restores normal vision to those for whom 
cataract was their only problem. Yet, in glaucoma, the 
loss of vision is due to death of the nerve cells called 
ganglion cells. These cells do not replace themselves 
as our skin cells do, for example.
So, to be able to restore vision, we must put back 
a lot of nerve cells. And, they can’t just be thrown into 
the retina, they have to go in the places where previous 
ones lived. And, they have to link up on one end with 
the other retinal nerve cells they normally get informa-
tion from, as well as to grow a fiber along those 2 inch-
es up to the brain, and link up with the partner cells in 
the next relay station. And, the connections (synapses) 
need to be made in a way that produces useful vision 
images, without messing up the existing connections 
for the parts of vision that haven’t been lost from glau-
coma already.
As you can see, that’s a lot of “And”s. But, 10 years 
ago, I held a meeting of scientists in which all the 
group talked about was how impossible it would ever 
be to restore vision in glaucoma. My lab and other 
research groups went to work and since then we’ve 
accomplished some of the initial steps. First, we know 
where we can get the nerve cells that we need — we 
can get them from your own eye. Within every eye are 
cells that made lots of daughter cells during life in the 
womb, then when the eye was “finished”, they went to 
sleep and stopped dividing. They’re alive, in the front 
part of the eye (the ciliary body), where we can get 
some out (surgically) without hurting the eye. Thou-
sands of new cells can be made from such a piece of 
removed tissue, and the beauty is that they are your 
cells, so there shouldn’t be a problem with rejection. 
That’s when someone else’s tissue is put into you and 
is attacked and killed since it’s foreign.
These new cells from inside the eye are called pro-
genitor cells. They went pretty far toward becoming 
eye cells during development prior to birth, then they 
stopped developing and stayed quietly in the eye, wait-
ing to be turned back on. Why don’t we want to use 
stem cells, which you have probably read about? Sci-
entists call something a stem cell when it can turn into 
many different things, like a bone cell, an ear cell, or 
a heart muscle cell. Stem cells are present in fetuses at 
an early stage after fertilization and we have learned 
a lot about development from them. But, there are ethi-
cal and practical issues involved in their use when they 
come from unborn fetuses. Other “stem cells” have been 
produced by treating adult cells in special ways. For 
these and for fetal stem cells, we would have to convince 
the stem cell that it wants to be an eye cell. Instead, the 
approach we have taken is to start with a progenitor cell 
that already had begun to be an eye cell. Furthermore, 
stem cells come from a different person and the body’s 
attempts to reject them would need to be treated.
Progenitor cells from the eye and from some other 
tissues (like the bone marrow where blood cells start) 
have been tested as replacements in the eye and there 
are some positive results. Progenitor cells have been 
convinced to move into the retina of animal eyes and 
have lived there for brief periods. No one has yet suc-
ceeded in finding a way to take the next steps: get-
ting the synapse connections wired up to the existing 
cells in the retina and growing a fiber up to the brain. 
We have plans that hopefully will beat those prob-
lems. But, more work is needed and no therapy will be 
available for a number of years.
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How can you help your family avoid  
glaucoma damage?
Take Home Points
 •   Tell your family about your glaucoma and have 
them get good exams
 •   Specific gene mutations have been found 
explaining a few glaucoma cases
 •   There are no standard gene tests that help most 
patients now
 •   Present genetic research may provide new tests 
in the future
Several years ago, we did a study that asked 100 
glaucoma patients to give us permission to call all their 
relatives and ask about glaucoma. We called 300 adult 
relatives of our patients and asked them what they knew 
about glaucoma, whether they knew they had a relative 
with it, if they knew it runs in families, and how often 
they had eye exams. Our results were disappointing. 
A lot of the family members did not know that they were 
at greater risk. The patients often hadn’t told family mem-
bers they have glaucoma. Some people aren’t that close 
to family, and other patients said that they didn’t think 
telling family members would lead them to do anything. 
“You know how grown kids are, they don’t listen to me 
when I tell them to get eye exams”, said one older patient.
Even worse, among the family members, more 
than half had never had a visual field test. Almost all of 
them said that they get their eyes “checked” every year, 
but they weren’t getting the best test for finding glau-
coma. We can’t tell if that was because their eye doctor 
was choosing not to do the test or if he/she didn’t know 
that the patient had a family history of glaucoma.
We tell every glaucoma patient to have all adult rela-
tives (mother, father, sisters, brothers, adult children) go 
once a year to an eye doctor and say the following exact 
words: “My mom has open angle (or angle closure) glau-
coma and I want a test of my angle and a visual field 
test.” This makes sure that the correct tests are done and 
repeated every year. If you don’t have glaucoma at age 40 
or 50, it can still develop later, increasingly after age 60. 
It may be that glaucoma severity is also inherited, mean-
ing that if you have a family member with severe vision 
loss from glaucoma, you are more likely to have that, too. 
People can’t really be sure that their grandmother real-
ly had glaucoma without seeing the actual records from 
past doctors’ exams. Having old records is very valuable.
It’s one thing to say that a disease “runs in families” 
and quite another to know how the specific gene defects 
underlie the inherited tendency. Each gene functions like 
a recipe, telling the cell the ingredients needed to make 
a protein that your body needs. People have about 
20,000 distinct genes, and scientists have only recently 
started to understand how some of them work. However, 
the process of looking for the “bad” genes has taught us 
some valuable lessons in medicine in the last 30 years. 
First, there is not one single gene that explains why peo-
ple get a common disease. Glaucoma, like other complex 
disorders, has genetic factors, environmental factors, 
and other contributing features, so simple answers like 
a mistake, called a mutation, in one gene will not explain 
why most people get the disease. Second, when a defect 
in one gene is found in persons with a disease, there 
are often several areas of the same gene that can have 
mutations or changes that alter what the gene makes. If 
there is a mistake in the recipe, the protein can come out 
wrong, and there are many places where a mistake could 
be made. So, even within the same gene that is defective, 
it can malfunction in different ways in different people. 
Third, the disease-causing aspect can be how much pro-
duct a gene makes rather than a defect in the gene code 
sequence for the molecule being made. Fourth, there 
are genetic disorders in which it takes two “hits” or gene 
defects in separate genes for the abnormality to happen 
(this is probably true for exfoliation syndrome.
Hunting for genetic risk factors can be done by one 
of two approaches. Scientists look at the DNA of fami-
lies with many members who have the disease, in a test 
called linkage analysis. They look for pieces of DNA that 
are linked to the presence of disease. In this method, 
the family relationships are very helpful for finding 
the gene, so the larger the family and more complete 
the information about who had the disease, the better. 
This method works best with rare mutations that greatly 
increase someone’s chances of getting the disease. The 
other method, called an association study, doesn’t use 
family information. In these studies, scientists compare 
the DNA of people who do or don’t have the disease and 
again look for pieces of DNA more frequently associated 
with disease than you would expect by chance.
For open angle glaucoma, several likely zones in the 
human genome have been found, with 3 that have now 
been pretty well established to contribute to a small num-
ber of cases. Genes for the protein molecules called myo-
cilin and optineurin are defective in certain subgroups of 
persons with open angle glaucoma. Myocilin mutations 
lead to high eye pressure at the age of 20 to 30 in families 
with this defect. Myocilin’s action, when abnormal, seems 
to block up outflow of aqueous humor. Optineurin muta-
tions are said to be more common in those with glauco-
ma at lower eye pressure. One hypothesis for how it causes 
damage is to make ganglion cells more sensitive to dying. 
For the subgroup with exfoliation syndrome, there are dif-
ferences in a chemical coded by the LOXL1 gene, whose 
function relates to the supporting tissues in the eye.
One might think that genetic testing of blood sam-
ples might be a good thing to do, to determine if you 
have one of these defects. Practically speaking, however, 
the chance that the average glaucoma patient has one 
of the known mutations is really very low. The tests are 
very expensive (thousands of dollars per gene tested) and 
are not done in routine labs. Having the specific muta-
tion or the variation in a particular zone (called a single 
nucleotide polymorphism or SNP) doesn’t mean that you 
have a 100% chance of glaucoma. So, at this time, it is 
only in research studies that gene testing has value.
To be continued in the 3-d part.
Поступила 30.06.2014
